PortalPublikationen24-hour blood pressure variability and treatment effect of i...

24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke

Standard

24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke. / Barow, Ewgenia; Boutitie, Florent; Cheng, Bastian; Cho, Tae-Hee; Ebinger, Martin; Endres, Matthias; Fiebach, Jochen B; Fiehler, Jens; Nickel, Alina; Puig, Josep; Roy, Pascal; Lemmens, Robin; Thijs, Vincent; Muir, Keith W; Nighoghossian, Norbert; Pedraza, Salvador; Simonsen, Claus Z; Gerloff, Christian; Thomalla, Götz.

in: EUR STROKE J, Jahrgang 6, Nr. 2, 06.2021, S. 168-175.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Barow, E, Boutitie, F, Cheng, B, Cho, T-H, Ebinger, M, Endres, M, Fiebach, JB, Fiehler, J, Nickel, A, Puig, J, Roy, P, Lemmens, R, Thijs, V, Muir, KW, Nighoghossian, N, Pedraza, S, Simonsen, CZ, Gerloff, C & Thomalla, G 2021, '24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke', EUR STROKE J, Jg. 6, Nr. 2, S. 168-175. https://doi.org/10.1177/23969873211014758

APA

Barow, E., Boutitie, F., Cheng, B., Cho, T-H., Ebinger, M., Endres, M., Fiebach, J. B., Fiehler, J., Nickel, A., Puig, J., Roy, P., Lemmens, R., Thijs, V., Muir, K. W., Nighoghossian, N., Pedraza, S., Simonsen, C. Z., Gerloff, C., & Thomalla, G. (2021). 24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke. EUR STROKE J, 6(2), 168-175. https://doi.org/10.1177/23969873211014758

Vancouver

Barow E, Boutitie F, Cheng B, Cho T-H, Ebinger M, Endres M et al. 24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke. EUR STROKE J. 2021 Jun;6(2):168-175. https://doi.org/10.1177/23969873211014758

Bibtex

@article{66dcccc9291d44de8f3b57d717586d62,
title = "24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke",
abstract = "Introduction: To assess the association between 24 h blood pressure variability (BPV) on functional outcome and treatment effect of intravenous alteplase in acute ischaemic stroke.Patients and methods: In all patients with acute ischaemic stroke of unknown onset randomised in the WAKE-UP (Efficacy and Safety of magnetic resonance imaging [MRI]-based Thrombolysis in Wake-Up Stroke) trial, blood pressure (BP) was measured before randomisation and after initiation of treatment at regular intervals up to 24 hours. Individual BPV was measured by coefficient of variation (CV) of all BP values. Primary outcome measure was favourable outcome defined by a modified Rankin Scale (mRS) score 0 or 1 at 90 days after stroke.Results: BP measurements were available for 498 of 503 patients randomised (177 women [35.5%], mean age [SD] of 65.2 [11.5] years). Systolic BPV was not associated with the treatment effect of thrombolysis (test for interaction, p = 0.46). The adjusted odds ratio (aOR) for favourable outcome with alteplase, adjusted for age, stroke severity and baseline BP on admission, did not show an association across the quintiles of increasing systolic BPV with an aOR 1.89 (95% confidence interval [CI], 0.76-4.70) in the lowest quintile to aOR 1.05 (95% CI, 0.43-2.56) in the highest quintile. Higher mean systolic BP was associated with a smaller treatment effect of thrombolysis with a significant interaction (p = 0.033). The aOR for favourable outcome with alteplase decreased with quintiles of increasing mean systolic BP from aOR 3.16 (95% CI, 1.26-7.93) in the lowest quintile to aOR 0.84 (95% CI, 0.34-2.10) in in the highest quintile.Conclusions: There was a significant interaction between mean systolic BP and treatment effect of thrombolysis with higher mean systolic BP being associated with poorer outcome. BPV was not associated with outcome after thrombolysis.ClinicalTrials.gov identifier NCT01525290.",
author = "Ewgenia Barow and Florent Boutitie and Bastian Cheng and Tae-Hee Cho and Martin Ebinger and Matthias Endres and Fiebach, {Jochen B} and Jens Fiehler and Alina Nickel and Josep Puig and Pascal Roy and Robin Lemmens and Vincent Thijs and Muir, {Keith W} and Norbert Nighoghossian and Salvador Pedraza and Simonsen, {Claus Z} and Christian Gerloff and G{\"o}tz Thomalla",
note = "{\textcopyright} European Stroke Organisation 2021.",
year = "2021",
month = jun,
doi = "10.1177/23969873211014758",
language = "English",
volume = "6",
pages = "168--175",
journal = "EUR STROKE J",
issn = "2396-9873",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - 24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke

AU - Barow, Ewgenia

AU - Boutitie, Florent

AU - Cheng, Bastian

AU - Cho, Tae-Hee

AU - Ebinger, Martin

AU - Endres, Matthias

AU - Fiebach, Jochen B

AU - Fiehler, Jens

AU - Nickel, Alina

AU - Puig, Josep

AU - Roy, Pascal

AU - Lemmens, Robin

AU - Thijs, Vincent

AU - Muir, Keith W

AU - Nighoghossian, Norbert

AU - Pedraza, Salvador

AU - Simonsen, Claus Z

AU - Gerloff, Christian

AU - Thomalla, Götz

N1 - © European Stroke Organisation 2021.

PY - 2021/6

Y1 - 2021/6

N2 - Introduction: To assess the association between 24 h blood pressure variability (BPV) on functional outcome and treatment effect of intravenous alteplase in acute ischaemic stroke.Patients and methods: In all patients with acute ischaemic stroke of unknown onset randomised in the WAKE-UP (Efficacy and Safety of magnetic resonance imaging [MRI]-based Thrombolysis in Wake-Up Stroke) trial, blood pressure (BP) was measured before randomisation and after initiation of treatment at regular intervals up to 24 hours. Individual BPV was measured by coefficient of variation (CV) of all BP values. Primary outcome measure was favourable outcome defined by a modified Rankin Scale (mRS) score 0 or 1 at 90 days after stroke.Results: BP measurements were available for 498 of 503 patients randomised (177 women [35.5%], mean age [SD] of 65.2 [11.5] years). Systolic BPV was not associated with the treatment effect of thrombolysis (test for interaction, p = 0.46). The adjusted odds ratio (aOR) for favourable outcome with alteplase, adjusted for age, stroke severity and baseline BP on admission, did not show an association across the quintiles of increasing systolic BPV with an aOR 1.89 (95% confidence interval [CI], 0.76-4.70) in the lowest quintile to aOR 1.05 (95% CI, 0.43-2.56) in the highest quintile. Higher mean systolic BP was associated with a smaller treatment effect of thrombolysis with a significant interaction (p = 0.033). The aOR for favourable outcome with alteplase decreased with quintiles of increasing mean systolic BP from aOR 3.16 (95% CI, 1.26-7.93) in the lowest quintile to aOR 0.84 (95% CI, 0.34-2.10) in in the highest quintile.Conclusions: There was a significant interaction between mean systolic BP and treatment effect of thrombolysis with higher mean systolic BP being associated with poorer outcome. BPV was not associated with outcome after thrombolysis.ClinicalTrials.gov identifier NCT01525290.

AB - Introduction: To assess the association between 24 h blood pressure variability (BPV) on functional outcome and treatment effect of intravenous alteplase in acute ischaemic stroke.Patients and methods: In all patients with acute ischaemic stroke of unknown onset randomised in the WAKE-UP (Efficacy and Safety of magnetic resonance imaging [MRI]-based Thrombolysis in Wake-Up Stroke) trial, blood pressure (BP) was measured before randomisation and after initiation of treatment at regular intervals up to 24 hours. Individual BPV was measured by coefficient of variation (CV) of all BP values. Primary outcome measure was favourable outcome defined by a modified Rankin Scale (mRS) score 0 or 1 at 90 days after stroke.Results: BP measurements were available for 498 of 503 patients randomised (177 women [35.5%], mean age [SD] of 65.2 [11.5] years). Systolic BPV was not associated with the treatment effect of thrombolysis (test for interaction, p = 0.46). The adjusted odds ratio (aOR) for favourable outcome with alteplase, adjusted for age, stroke severity and baseline BP on admission, did not show an association across the quintiles of increasing systolic BPV with an aOR 1.89 (95% confidence interval [CI], 0.76-4.70) in the lowest quintile to aOR 1.05 (95% CI, 0.43-2.56) in the highest quintile. Higher mean systolic BP was associated with a smaller treatment effect of thrombolysis with a significant interaction (p = 0.033). The aOR for favourable outcome with alteplase decreased with quintiles of increasing mean systolic BP from aOR 3.16 (95% CI, 1.26-7.93) in the lowest quintile to aOR 0.84 (95% CI, 0.34-2.10) in in the highest quintile.Conclusions: There was a significant interaction between mean systolic BP and treatment effect of thrombolysis with higher mean systolic BP being associated with poorer outcome. BPV was not associated with outcome after thrombolysis.ClinicalTrials.gov identifier NCT01525290.

U2 - 10.1177/23969873211014758

DO - 10.1177/23969873211014758

M3 - SCORING: Journal article

C2 - 34414292

VL - 6

SP - 168

EP - 175

JO - EUR STROKE J

JF - EUR STROKE J

SN - 2396-9873

IS - 2

ER -